DFTX - Mind Medicine (MindMed) Inc.

21.16
-0.240   -1.134%

Share volume: 990,299
Last Updated: 05-12-2026
Pharmaceutical Products/Medicinal Chemicals: 0.85%

PREVIOUS CLOSE
CHG
CHG%
$21.40
-0.24
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
56%
Profitability 50%
Dept financing 38%
Liquidity 43%
Performance 70%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-4.04%
1 Month
-4.90%
3 Months
34.35%
6 Months
81.94%
1 Year
232.18%
2 Year
150.41%
Key data
Stock price
$21.16
P/E Ratio 
0.00
DAY RANGE
$20.93 - $21.45
EPS 
-$2.50
52 WEEK RANGE
$6.28 - $26.25
52 WEEK CHANGE
$223.55
MARKET CAP 
1.884 B
YIELD 
N/A
SHARES OUTSTANDING 
109.067 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-07-2025
BETA 
1.95
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,444,450
AVERAGE 30 VOLUME 
$1,932,758
Company detail
CEO: Robert Barrow
Region: US
Website: mindmed.co
Employees: 40
IPO year: 2016
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Medicinal Chemicals
Sector: Manufacturing

Mind Medicine (MindMed) Inc. develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder.

Recent news